These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28365051)

  • 1. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
    Gadgeel SM
    Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
    [No Abstract]   [Full Text] [Related]  

  • 2. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.
    Iams WT; Lovly CM
    Cancer J; 2015; 21(5):378-82. PubMed ID: 26389762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resensitizing Refractory ALK+ NSCLC: A Case Study.
    Poh A
    Cancer Discov; 2016 Mar; 6(3):220-1. PubMed ID: 26801737
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.
    De Pas T; Pala L; Catania C; Conforti F
    Future Oncol; 2017 Dec; 13(29):2629-2644. PubMed ID: 28891712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
    Shaw AT
    Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
    [No Abstract]   [Full Text] [Related]  

  • 6. Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2017 Jun; 18(6):36. PubMed ID: 28534251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How should "RET positive" NSCLC be treated?
    Smit EF
    Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
    [No Abstract]   [Full Text] [Related]  

  • 8. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
    Kaczmar J; Mehra R
    Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes].
    Besse B
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S93-5. PubMed ID: 26118884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First macrocyclic 3
    Basit S; Ashraf Z; Lee K; Latif M
    Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
    Sequist LV
    Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
    [No Abstract]   [Full Text] [Related]  

  • 14. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-over-it's a feature, not a bug.
    Engelsberg A
    Ann Oncol; 2015 Sep; 26(9):2000-2002. PubMed ID: 26078468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime time.
    Socinski MA
    Oncology (Williston Park); 2011 Jun; 25(7):601, 604, 607. PubMed ID: 21888259
    [No Abstract]   [Full Text] [Related]  

  • 17. Alectinib for treatment of ALK-positive non-small-cell lung cancer.
    Avrillon V; Pérol M
    Future Oncol; 2017 Feb; 13(4):321-335. PubMed ID: 27780368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Chuang JC; Neal JW; Niu XM; Wakelee HA
    Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Horizon
--interpretation of ALK-positive non-small cell lung cancer Chinese story].
    Liu X
    Zhongguo Fei Ai Za Zhi; 2015 Feb; 18(2):59-60. PubMed ID: 25676396
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.